Olink Holding AB

Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. The firm offers a platform of products and services which are deployed across major biopharmaceutical companies and clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. It operates through the following segments: Kit and Service. The company was founded on December 13, 2018 and is headquartered in Uppsala, Sweden.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Olink Holding AB exceeds revenue goals, eyes proteomics market growth

Olink had a successful Q4 and 2022, exceeding revenue goals and showcasing innovation.
The company is poised for growth in the proteomics market with a focus on data quality.
Challenges include shifting revenue mix, expanding installations, and meeting customer demands.
Opportunities lie in developing new assays, expanding the protein library, and leveraging positive customer feedback.

Olink Holding AB reports robust Q1 growth and eyes profitability

Olink Holding AB's Q1 2023 performance reflects strong revenue growth and a focus on innovation in next-generation proteomics.
Despite challenges in certain regions and operating at a net loss, the company maintains positive cash flow and aims for profitability in 2023.
Opportunities lie in market expansion, M&A activities, and improving kit gross margins through R&D efforts.
Overall, Olink's unique positioning in the life science space and commitment to serving diverse customer needs underpin its growth potential.

Olink Holding AB (OLK) sees strong revenue growth and market optimism

Olink Holding AB (OLK) reports solid revenue growth in Q2 2023, driven by Explore revenue and scientific productivity. Despite challenges in profitability and margin improvements, the company is optimistic about the market impact of Explore HT and back-half growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science.

Cricut

Janux Therapeutics

Loop Industries

Omega Flex

Red Violet

Vigil Neuroscience

Short-squeeze stocks offer tremendous upside potential for people who laugh in the face of danger. Fundamentally, the concept involves betting against the pessimistic crowd with the aim of sparking a reactionary panic.

7 Short-Squeeze Stocks to Buy for Contrarian Investors

UPPSALA, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that it has entered into an agreement with Discovery Life Sciences™ (Discovery) to establish the largest commercial platform of the Olink® technology in the Americas outside of Olink, and provide the market with a global "one-stop shop" to support the discovery and validation of proteomics at scale and with high specificity across all major biological pathways and sample matrices.

Discovery Life Sciences partners with Olink to support proteomics research and accelerate precision medicine programs

HUNTSVILLE, Ala. , Sept. 20, 2022 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, has entered into an agreement with Olink Holding AB (publ) (Olink) and is installing the largest commercial platform of the Olink® technology in the Americas outside of Olink itself to become a leading global certified service provider for the Olink Proximity Extension Assay (PEA) technology, a unique anti-body based proteomic technology.

DISCOVERY LIFE SCIENCES INSTALLS THE LARGEST OLINK PLATFORM IN THE AMERICAS TO SUPPORT PROTEOMICS RESEARCH & BIOMARKER DEVELOPMENT AT SCALE

UPPSALA, Sweden, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based in China, successfully completed extended concordance testing on Olink's platforms (Olink® Target 48/96 and Olink® Explore), fulfilling specific requirements that supplement the Olink quality acceptance criteria. This latest validation was initiated by and implemented in cooperation with a leading global pharmaceutical company.

Multi-omics service provider Sequanta completes extended concordance validation of Olink® Target 48/96 and Olink® Explore

UPPSALA, Sweden, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced several appointments in its leadership structure.

Olink strengthens management team for continued leadership in the modern proteomics era

UPPSALA, Sweden, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor conferences:

Olink to participate in September investor conferences

Olink Holding AB (publ) (NASDAQ:OLK ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET CompanyParticipants Jon Heimer - CEO Oskar Hjelm - CFO Carl Raimond - CCO Jan Medina - VP, IR & Capital Markets Conference Call Participants Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Puneet Souda - SVB Securities Operator Good day and welcome to the Olink Proteomics Second Quarter 2022 Earnings Conference Call [Operator instructions]. As a reminder, this call may be recorded.

Olink Holding AB (publ) (OLK) CEO Jon Heimer on Q2 2022 Results - Earnings Call Transcript

Olink Holding AB publ Sponsored ADR (OLK) delivered earnings and revenue surprises of 69.23% and 3.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Olink Holding AB publ Sponsored ADR (OLK) Reports Q2 Loss, Tops Revenue Estimates

UPPSALA, Sweden, July 14, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the second quarter of 2022 before the market open on Thursday, August 11, 2022. Company management will host a conference call to discuss these results at 8:00 am ET.

Olink to report second quarter 2022 financial results on August 11, 2022

UPPSALA, Sweden, June 28, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the release of Olink® Analyze 3.1. Olink® Analyze is an R software package, a collection of functions written in R programming language, created to streamline the analysis of Olink data.

Release of Olink® Analyze 3.1 streamlines proteomic analysis to connect data to biological insight

UPPSALA, Sweden, June 21, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) announced that a publication describing the early findings of proteomics research conducted by the UK Biobank Pharma Proteomics Project (UKB-PPP) was published online to the bioRxiv preprint server, and is available here.

UK Biobank Pharma Proteomics Project publishes early results from its pioneering proteomics research

Olink Holding AB publ Sponsored ADR (OLK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Olink Holding AB publ Sponsored ADR (OLK) Surges 7.3%: Is This an Indication of Further Gains?

UPPSALA, Sweden, June 16, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the Human Genomics Facility of the Erasmus Medical Center in Rotterdam has adopted the Olink technology, becoming the first Olink® Explore certified laboratory in the Netherlands.

Erasmus Medical Center, Rotterdam is partnering with Olink to deepen understanding of disease progression and accelerate the development of novel therapies

Proof of concept data show potential to combine the Olink® Explore assay with readout on Ultima Genomics' sequencing platform for high-throughput proteomics applications Olink continues its pioneering efforts to enable Explore broadly across genomics ecosystems and to democratize next-generation proteomics UPPSALA, Sweden , June 8, 2022 /PRNewswire/ -- Olink Holding AB (publ) ("Olink") (Nasdaq: OLK) and Ultima Genomics ("Ultima") today announced that they have entered into a collaboration to enable the use of the Olink® Explore high-throughput proteomics platform with Ultima's sequencing architecture. Ultima Genomics and Olink are working towards a seamless pairing of the existing Olink® Explore assay and Ultima Genomics' sequencing system, and are collaborating with joint customers to enable larger-scale projects.

Ultima Genomics and Olink collaborate to develop solution for high-throughput proteomics

Element Biosciences to provide proof-of-concept findings during panel discussion a t the Advances in Genome Biology and Technology (AGBT) general meeting

Element Biosciences and Olink collaborate to enable Olink® Explore on the Element AVITI™ System

Max Read kits on the G4 Sequencing Platform will produce up to 4 b illion reads per run, enabling high throughput , cost-effective proteomics research

Singular Genomics and Olink collaborate to enable Olink® Explore on the G4 Max Read™ sequencing kits

Olink Holding AB (publ) (NASDAQ:OLK ) Q1 2022 Results Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Jan Medina - Vice President, Investor Relations & Capital Markets Jon Heimer - Chief Executive Officer Oskar Hjelm - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Puneet Souda - SVB Securities Tejas Savant - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Olink Proteomics First Quarter 2022 Earnings Conference Call.

Olink Holding AB (publ) (OLK) CEO Jon Heimer on Q1 2022 Results - Earnings Call Transcript

Olink Holding AB went public in March 2021, raising around $353 million in gross proceeds for the company and selling shareholders in an IPO. The firm sells proteomics research equipment and services worldwide.

Olink Holding Plans Strong 2022 Spending Amid Growth Slowdown

Olink Holding AB publ Sponsored ADR (OLK) delivered earnings and revenue surprises of 41.18% and 12.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Olink Holding AB publ Sponsored ADR (OLK) Reports Q1 Loss, Tops Revenue Estimates

UPPSALA, Sweden, May 12, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter of 2022.

Olink reports first quarter 2022 financial results

UPPSALA, Sweden, May 09, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Oxford Genomics at the University of Oxford adopts the Olink technology and becomes the first Olink certified laboratory in the United Kingdom. The partnership will enable novel techniques to unravel mechanisms of disease using the Olink® Explore platform.

University of Oxford adopts Olink technology to advance protein biomarker discovery and unravel mechanisms of disease

UPPSALA, Sweden, April 21, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the first quarter of 2022 before the market open on Thursday, May 12, 2022. Company management will host a conference call to discuss these results at 8:00 am ET.

Olink to report first quarter 2022 financial results on May 12, 2022

UPPSALA, Sweden, April 07, 2022 (GLOBE NEWSWIRE) -- At the A nnual G eneral M eeting (the “AGM”) of Olink Holding AB (publ), reg. no 55 9189 - 7755 , (the “Company”), on 7 April 202 2 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www. olink .com .

Report from the Annual General Meeting of Olink Holding AB (publ) on 7 April 2022

UPPSALA, Sweden, March 17, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2021 is now available on the Company's website at https://investors.olink.com/.

Olink publishes 2021 annual report

UPPSALA, Sweden, March 09, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced its collaboration with TATAA Biocenter, a leading European provider of molecular analysis services, launching Olink ® E xplore 3072 proteome profiling service.

News for Olink Holding AB Stock (OLK)